Södertälje, Sweden

Johan Sundell

This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Astrazeneca Ab. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Johan Sundell. Retrieved from https://idiyas.com/inventor/johan-sundell

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank
USPTO Granted Patents = 2 

% Patents Active = 50.0

Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Johan Sundell: Inventor in GLP-1 Receptor Modulator Research.

Introduction

Johan Sundell is an inventor based in Södertälje, Sweden. His patent work includes compounds investigated as glucagon-like peptide-1 (GLP-1) receptor modulators, a field relevant to potential treatments for metabolic conditions and cardiovascular disease. Sundell is associated with AstraZeneca AB and has 2 patents.

Latest Patents

Sundell’s listed patents concern chemical compounds, pharmaceutical compositions, and potential therapeutic uses.

“Certain 3-azabicyclo[3.1.0]hexanes as GLP-1 receptor modulators” discloses 3-azabicyclo[3.1.0]hexanes and their pharmaceutically acceptable salts, along with compositions containing them and their use in therapy. The compounds are described as GLP-1 receptor modulators with potential applications in treating or preventing cardiovascular disease and metabolic conditions, including Type 2 diabetes.

“Certain 2,5-diazabicyclo[4.2.0]octanes and octahydrofuro[3,4-b]pyrazines as GLP-1 receptor modulators” describes compounds from the named chemical classes and their pharmaceutically acceptable salts. It also covers compositions containing these compounds and their therapeutic use, including potential treatment or prevention of cardiovascular disease and metabolic conditions such as Type 2 diabetes.

Career Highlights

Sundell’s listed patent portfolio focuses on medicinal chemistry and GLP-1 receptor modulation. The patent descriptions identify possible therapeutic applications, but do not establish that the compounds are approved medicines or proven treatments.

Collaborations

Sundell is associated with AstraZeneca AB. His listed coworkers include Ekaterina Ratkova and Joakim Bergman.

Conclusion

Johan Sundell’s two listed patents center on GLP-1 receptor modulator compounds and their potential therapeutic applications, reflecting a focus on pharmaceutical innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…